Regeneron Pharmaceuticals Stock

Regeneron Pharmaceuticals Dividend 2024

Regeneron Pharmaceuticals Dividend

0 USD

Regeneron Pharmaceuticals Dividend yield

Ticker

REGN

ISIN

US75886F1075

WKN

881535

How much dividend does Regeneron Pharmaceuticals 2024 pay?

According to the latest status from November 2024, Regeneron Pharmaceuticals paid a total of 0 USD per share in dividends within the last 12 months. With the current Regeneron Pharmaceuticals price of 738 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Regeneron Pharmaceuticals Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Regeneron Pharmaceuticals Dividend Safe?

Regeneron Pharmaceuticals has been increasing the dividend for 0 years.

Over the past 10 years, Regeneron Pharmaceuticals has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Regeneron Pharmaceuticals revenue by segment

  • 100 % Medicines

Dividend Details

Understanding Regeneron Pharmaceuticals's Dividend Distributions

Regeneron Pharmaceuticals’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Regeneron Pharmaceuticals's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Regeneron Pharmaceuticals's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Regeneron Pharmaceuticals’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Regeneron Pharmaceuticals Aktienanalyse

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals Inc. is an American biotechnology company founded in 1988 by Leonard Schleifer. The company is headquartered in Tarrytown, New York and employs approximately 8,500 people worldwide. Regeneron is known for its research in the areas of cancer therapies, eye diseases, and asthma. Regeneron operates a business model based on the research and development of biotechnological drugs. The company invests heavily in research and seeks new compounds that can fight inflammation and cancer. Regeneron develops its products using the reverse transcriptase polymerase chain reaction (RT-PCR), a method for amplifying RNA molecules into DNA. This method allows for the rapid production and analysis of large amounts of genetic material. The company is divided into several divisions, including ophthalmology, inflammatory diseases, oncology, and neurology. Regeneron also produces a wide range of biopharmaceutical products, including antibodies, interleukins, enzymes, and fusion proteins. One of Regeneron's most popular products is EYLEA (Aflibercept), a medication used to treat retinal diseases such as age-related macular degeneration. EYLEA has been on the market since 2011 and has proven to be highly effective. The medication is a blockbuster for Regeneron and accounts for a significant portion of its product revenue. Another important product from Regeneron is Dupixent (Dupilumab), a medication used to treat atopic dermatitis and severe asthma. The medication has been on the market since 2017 and has quickly established itself as a key treatment for asthma. Dupixent is produced in collaboration with Sanofi. Regeneron has also conducted promising research in the field of oncology. The company has developed a range of cancer therapies that are in the clinical phase of development. One example is the antibody Libtayo, which is used to treat squamous cell carcinomas. In its recent history, Regeneron has played a major role in the research and development of antibodies for the treatment of COVID-19. Regeneron was the first company to receive funding from the US government for the development of an antibody cocktail for the treatment of COVID-19. The medication, consisting of the antibodies Casirivimab and Imdevimab, was granted emergency use authorization by the US Food and Drug Administration in November 2020. Regeneron also has an extensive partnership with pharmaceutical company Sanofi. The two companies have jointly developed products such as Praluent (Alirocumab), a medication used to lower cholesterol levels, and Kevzara (Sarilumab), a medication used to treat rheumatoid arthritis. Overall, in recent years, Regeneron has built a strong position as a leading biotechnology company. The company has an impressive product pipeline and has developed a wide range of important medications. Regeneron continues to work on the development of new therapies and has the potential to play a significant role in the biotechnology industry in the coming years. Regeneron Pharmaceuticals is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Regeneron Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Frequently Asked Questions about Regeneron Pharmaceuticals stock

How much dividend does Regeneron Pharmaceuticals pay?

Over the past 12 months, Regeneron Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regeneron Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Regeneron Pharmaceuticals?

The current dividend yield of Regeneron Pharmaceuticals is .

When does Regeneron Pharmaceuticals pay dividends?

Regeneron Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Regeneron Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Regeneron Pharmaceuticals located?

Regeneron Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Regeneron Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Regeneron Pharmaceuticals from 11/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/24/2024.

When did Regeneron Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/24/2024.

What was the dividend of Regeneron Pharmaceuticals in the year 2023?

In the year 2023, Regeneron Pharmaceuticals distributed 0 USD as dividends.

In which currency does Regeneron Pharmaceuticals pay out the dividend?

The dividends of Regeneron Pharmaceuticals are distributed in USD.

Andere Kennzahlen von Regeneron Pharmaceuticals

Our stock analysis for Regeneron Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regeneron Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.